HepaTx Collaboration Reports 95 Percent Success Rate in Second Phase

Founded in 1990, SP Investment Fund, LLC, invests in government-subsidized apartment buildings and emerging technology. SP Investment Fund was an early investor in HepaTx Corporation, a regenerative medicine company developing new types of stem cell-based treatments for patients with late-stage liver disease.

HepaTx’s proprietary process, licensed from Stanford and well protected by licensed IP, differentiates adipose stromal cells obtained from discarded lipoaspirate into functional hepatocytes. These hepatocytes are directly infused into the liver where they regenerate liver function.

HepaTx recently completed a second phase collaborative study with Namocell and Takara that demonstrates a 95% reproducibility of results that will allow it to developer cell therapies for individuals with late stage liver disease. Dr. Eric Schuur, CEO of HepaTx, said Namocell’s Single Cell Dispensers facilitated the retrieval of reliable phenotype data from cells during the trial phase. He also highlighted the ability of Takara Bio’s SMART-seq kits to produce both consistent sample quality and a high level of information.

via WordPress https://ift.tt/35J4aEU